Effect of RECK gene polymorphisms on hepatocellular carcinoma susceptibility and clinicopathologic features

PLoS ONE

Volumn 7, Issue 3, 2012, Pages

  Chung, Tsung Te ^a,b   Yeh, Chao Bin ^a,c   Li, Yi Ching ^a   Su, Shih Chi ^d   Chien, Ming Hsien ^e,f   Yang, Shun Fa ^a   Hsieh, Yi Hsien ^a,c  

^a CHUNG SHAN MEDICAL UNIVERSITY   (Taiwan)

^b SHOW CHWAN MEMORIAL HOSPITAL   (Taiwan)

^c CHUNG SHAN MEDICAL UNIVERSITY HOSPITAL   (Taiwan)

^d UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^e TAIPEI MEDICAL UNIVERSITY   (Taiwan)

^f TAIPEI MEDICAL UNIVERSITY   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; ALPHA FETOPROTEIN; ASPARTATE AMINOTRANSFERASE; GENOMIC DNA; GLYCOSYLPHOSPHATIDYLINOSITOL ANCHORED PROTEIN; PRIMER DNA; RECK PROTEIN, HUMAN;

ADULT; ALLELE; ARTICLE; CANCER PATIENT; CANCER RISK; CANCER SIZE; CANCER STAGING; CANCER SUSCEPTIBILITY; CLINICAL FEATURE; CONTROLLED STUDY; DISTANT METASTASIS; FEMALE; GENE; GENETIC ASSOCIATION; GENOTYPE; HETEROZYGOTE; HISTOPATHOLOGY; HOSPITAL BASED CASE CONTROL STUDY; HUMAN; HUMAN TISSUE; LIVER CARCINOGENESIS; LIVER CELL CARCINOMA; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; PROMOTER REGION; REAL TIME POLYMERASE CHAIN REACTION; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; REVERSION INDUCING CYSTEINE RICH PROTEIN WITH KAZAL MOTIF GENE; RISK ASSESSMENT; RISK FACTOR; SINGLE NUCLEOTIDE POLYMORPHISM; TAIWAN; WILD TYPE; CASE CONTROL STUDY; GENETIC PREDISPOSITION; GENETICS; LIVER TUMOR; METASTASIS; NONPARAMETRIC TEST; STATISTICAL MODEL;

CARCINOMA, HEPATOCELLULAR; CASE-CONTROL STUDIES; DNA PRIMERS; GENETIC ASSOCIATION STUDIES; GENETIC PREDISPOSITION TO DISEASE; GPI-LINKED PROTEINS; HUMANS; LIVER NEOPLASMS; LOGISTIC MODELS; NEOPLASM METASTASIS; POLYMORPHISM, RESTRICTION FRAGMENT LENGTH; POLYMORPHISM, SINGLE NUCLEOTIDE; REAL-TIME POLYMERASE CHAIN REACTION; RISK FACTORS; STATISTICS, NONPARAMETRIC; TAIWAN;

EID: 84863238896     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0033517     Document Type: Article

References (33)

1. Ferlay J, Shin HR, Bray F, Forman D, Mathers C, et al. (2010) Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer 127: 2893-2917.
2. Chien MH, Yeh KT, Li YC, Hsieh YH, Lin CH, et al. (2011) Effects of E-cadherin (CDH1) gene promoter polymorphisms on the risk and clinicopathological development of hepatocellular carcinoma. J Surg Oncol 104: 299-304.
3. Farazi PA, DePinho RA, (2006) Hepatocellular carcinoma pathogenesis: from genes to environment. Nat Rev Cancer 6: 674-687.
4. El-Serag HB, Rudolph KL, (2007) Hepatocellular carcinoma: epidemiology and molecular carcinogenesis. Gastroenterology 132: 2557-2576.
5. Weng CJ, Tsai CM, Chen YC, Hsieh YH, Lin CW, et al. (2010) Evaluation of the association of urokinase plasminogen activator system gene polymorphisms with susceptibility and pathological development of hepatocellular carcinoma. Ann Surg Oncol 17: 3394-3401.
6. Weng CJ, Hsieh YH, Tsai CM, Chu YH, Ueng KC, et al. (2010) Relationship of insulin-like growth factors system gene polymorphisms with the susceptibility and pathological development of hepatocellular carcinoma. Ann Surg Oncol 17: 1808-1815.
7. Chen TY, Li YC, Liu YF, Tsai CM, Hsieh YH, et al. (2011) Role of MMP14 gene polymorphisms in susceptibility and pathological development to hepatocellular carcinoma. Ann Surg Oncol 18: 2348-2356.
8. Takahashi C, Sheng Z, Horan TP, Kitayama H, Maki M, et al. (1998) Regulation of matrix metalloproteinase-9 and inhibition of tumor invasion by the membrane-anchored glycoprotein RECK. Proc Natl Acad Sci U S A 95: 13221-13226.
9. Noda M, Oh J, Takahashi R, Kondo S, Kitayama H, et al. (2003) RECK: a novel suppressor of malignancy linking oncogenic signaling to extracellular matrix remodeling. Cancer Metastasis Rev 22: 167-175.
10. Oh J, Takahashi R, Kondo S, Mizoguchi A, Adachi E, et al. (2001) The membrane-anchored MMP inhibitor RECK is a key regulator of extracellular matrix integrity and angiogenesis. Cell 107: 789-800.
11. Masui T, Doi R, Koshiba T, Fujimoto K, Tsuji S, et al. (2003) RECK expression in pancreatic cancer: its correlation with lower invasiveness and better prognosis. Clin Cancer Res 9: 1779-1784.
12. Lei H, Hemminki K, Altieri A, Johansson R, Enquist K, et al. (2007) Promoter polymorphisms in matrix metalloproteinases and their inhibitors: few associations with breast cancer susceptibility and progression. Breast Cancer Res Treat 103: 61-69.
13. Takenaka K, Ishikawa S, Kawano Y, Yanagihara K, Miyahara R, et al. (2004) Expression of a novel matrix metalloproteinase regulator, RECK, and its clinical significance in resected non-small cell lung cancer. Eur J Cancer 40: 1617-1623.
14. Takeuchi T, Hisanaga M, Nagao M, Ikeda N, Fujii H, et al. (2004) The membrane-anchored matrix metalloproteinase (MMP) regulator RECK in combination with MMP-9 serves as an informative prognostic indicator for colorectal cancer. Clin Cancer Res 10: 5572-5579.
15. Song SY, Son HJ, Nam E, Rhee JC, Park C, (2006) Expression of reversion-inducing-cysteine-rich protein with Kazal motifs (RECK) as a prognostic indicator in gastric cancer. Eur J Cancer 42: 101-108.
16. Rabien A, Burkhardt M, Jung M, Fritzsche F, Ringsdorf M, et al. (2007) Decreased RECK expression indicating proteolytic imbalance in prostate cancer is associated with higher tumor aggressiveness and risk of prostate-specific antigen relapse after radical prostatectomy. Eur Urol 51: 1259-1266.
17. Takemoto N, Tada M, Hida Y, Asano T, Cheng S, et al. (2007) Low expression of reversion-inducing cysteine-rich protein with Kazal motifs (RECK) indicates a shorter survival after resection in patients with adenocarcinoma of the lung. Lung Cancer 58: 376-383.
18. Long NK, Kato K, Yamashita T, Makita H, Toida M, et al. (2008) Hypermethylation of the RECK gene predicts poor prognosis in oral squamous cell carcinomas. Oral Oncol 44: 1052-1058.
19. Qi M, Li JS, Li Y, (2010) [Clinicopathological significance of expressions of RECK and MMP-2 in esophageal squamous carcinoma]. Zhonghua Zhong Liu Za Zhi 32: 283-285.
20. Xu J, Wu S, Shi X, (2010) Expression of matrix metalloproteinase regulator, RECK, and its clinical significance in osteosarcoma. J Orthop Res 28: 1621-1625.
21. Chung TT, Pan MS, Kuo CL, Wong RH, lin CW, et al. (2011) Impact of RECK gene polymorphisms and environmental factors on oral cancer susceptibility and clinicopathologic characteristics in Taiwan. Carcinogenesis 32: 1063-1068.
22. Li Y, Zhang Y, Zheng Q, (2005) Expression of RECK gene and MMP-9 in hilar cholangiocarcinoma and its clinical significance. J Huazhong Univ Sci Technolog Med Sci 25: 552-554.
23. Zavras AI, Yoon AJ, Chen MK, Lin CW, Yang SF, (2011) Metallothionein-1 genotypes in the risk of oral squamous cell carcinoma. Ann Surg Oncol 18: 1478-1483.
24. Furumoto K, Arii S, Mori A, Furuyama H, Gorrin Rivas MJ, et al. (2001) RECK gene expression in hepatocellular carcinoma: correlation with invasion-related clinicopathological factors and its clinical significance. Reverse-inducing-cysteine-rich protein with Kazal motifs. Hepatology 33: 189-195.
25. Vauthey JN, Lauwers GY, Esnaola NF, Do KA, Belghiti J, et al. (2002) Simplified staging for hepatocellular carcinoma. J Clin Oncol 20: 1527-1536.
26. Eisenberg I, Hochner H, Sadeh M, Argov Z, Mitrani-Rosenbaum S, (2002) Establishment of the genomic structure and identification of thirteen single-nucleotide polymorphisms in the human RECK gene. Cytogenet Genome Res 97: 58-61.
27. Murugan RS, Vinothini G, Hara Y, Nagini S, (2009) Black tea polyphenols target matrix metalloproteinases, RECK, proangiogenic molecules and histone deacetylase in a rat hepatocarcinogenesis model. Anticancer Res 29: 2301-2305.
28. Sasahara RM, Takahashi C, Noda M, (1999) Involvement of the Sp1 site in ras-mediated downregulation of the RECK metastasis suppressor gene. Biochem Biophys Res Commun 264: 668-675.
29. Sasahara RM, Takahashi C, Sogayar MC, Noda M, (1999) Oncogene-mediated downregulation of RECK, a novel transformation suppressor gene. Braz J Med Biol Res 32: 891-895.
30. Schmidt CM, McKillop IH, Cahill PA, Sitzmann JV, (1997) Increased MAPK expression and activity in primary human hepatocellular carcinoma. Biochem Biophys Res Commun 236: 54-58.
31. Okabe H, Satoh S, Kato T, Kitahara O, Yanagawa R, et al. (2001) Genome-wide analysis of gene expression in human hepatocellular carcinomas using cDNA microarray: identification of genes involved in viral carcinogenesis and tumor progression. Cancer Res 61: 2129-2137.
32. Li SL, Gao DL, Zhao ZH, Liu ZW, Zhao QM, et al. (2007) Correlation of matrix metalloproteinase suppressor genes RECK, VEGF, and CD105 with angiogenesis and biological behavior in esophageal squamous cell carcinoma. World J Gastroenterol 13: 6076-6081.
33. Chang HC, Cho CY, Hung WC, (2007) Downregulation of RECK by promoter methylation correlates with lymph node metastasis in non-small cell lung cancer. Cancer Sci 98: 169-173.